Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin)

Wahid, Braira; Shami, Khadija; Joiya, Salman A.; Özuyar, Sevilay E. G.; Idrees, Muhammad

doi:10.1002/jmv.25931

Cited by 4 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, in a study of Wahid et al [ 29 ], performed on a limited number of patients (37 patients on sofosbuvir and 26 IFN-α treated patients), was reported high prevalence of hypothyroidism in both groups, with 18.9% observed in sofosbuvir group. In a more recent study, Wahid et al [ 30 ] confirmed a high risk of hypothyroidism in two groups of HCV patients treated with different DAAs drugs regimens (sofosbuvir + IFN-α + ribavirin and sofosbuvir + daclatasvir + ribavirin), with higher prevalence of hypothyroidism in the first DAAs group. Eletreby et al [ 31 ] studied a very large number of HCV naïve patients (13,402 patients), detecting at baseline a total of 21.1% of hypothyroidism.…”

Section: Discussionmentioning

confidence: 98%

Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity

Rodia

Meloni

Mascia

et al. 2022

J Endocrinol Invest

View full text Add to dashboard Cite

Purpose It is well known that interferon-α (IFN-α), used for long time as the main therapy for HCV-related disease, induces thyroid alterations, but the impact of the new direct-acting antivirals (DAAs) on thyroid is not established. Aim of this prospective study was to evaluate if DAAs therapy may induce thyroid alterations. Methods A total of 113 HCV patients, subdivided at the time of the enrollment in naïve group (n = 64) and in IFN-α group (n = 49) previously treated with pegylated interferon-α and ribavirin, were evaluated for thyroid function and autoimmunity before and after 20–32 weeks of DAAs. Results Before starting DAAs, a total of 8/113 (7.1%) patients showed Hashimoto's thyroiditis (HT) all belonging to IFN-α group (8/49, 16.3%), while no HT cases were found in the naïve group. Overall, 7/113 (6.2%) patients were hypothyroid: 3/64 (4.7%) belonging to naïve group and 4/49 (8.2%) to IFN-α group. Furthermore, a total of 8/113 patients (7.1%) showed subclinical hyperthyroidism: 2/64 (3.1%) were from naïve group and 6/49 (12.2%) from IFN-α group. Interestingly, after DAAs therapy, no new cases of HT, hypothyroidism and hyperthyroidism was found in all series, while 6/11 (54.5%) patients with non-autoimmune subclinical thyroid dysfunction became euthyroid. Finally, the only association between viral genotypes and thyroid alterations was genotype 1 and hypothyroidism. Conclusions This study supports evidence that DAAs have a limited or missing influence on thyroid in patients with HCV-related diseases. Moreover, it provides preliminary evidence that subclinical non-autoimmune thyroid dysfunction may improve after HCV infection resolution obtained by DAAs.

show abstract

Section: Discussionmentioning

confidence: 98%

Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity

Rodia

Meloni

Mascia

et al. 2022

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

“…Since Isaacs and Lindenmann (7) discovered IFN, many studies have shown that besides antiviral activity it acts as a macrophage activating factor and reduces tumour cell division. However, despite its known activity against viruses, currently only a few drugs have been approved by the US Food and Drug Administration (FDA) for the treatment of viral hepatitis B and C (20). The therapeutic efficacy of alpha-interferon has been recognised by scholars from all over the world (6,9,19).…”

Section: Introductionmentioning

confidence: 99%

Acute and sub-chronic toxicity study of recombinant bovine interferon alpha in rodents

Gao

Zhou³

et al. 2021

Journal of Veterinary Research

View full text Add to dashboard Cite

Introduction Recombinant bovine interferon alpha (rBoIFN-α) has been demonstrated to have antiviral activity. However, no conduct of acute or chronic toxicity tests has been reported. Material and Methods Specific pathogen-free Sprague Dawley rats were administered doses at different concentrations through intraperitoneal or intravenous injection. After the administration (single for an acute toxicity test over 14 days or daily for a sub-chronic toxicity test over 30 days), the rats’ behaviour and other indicators and the degree of toxic reaction were continuously monitored. Blood was collected for haematological and serum biochemical examinations. At the end of the experiments, the rats were sacrificed for necropsy and histopathological tissue analysis. Results The external performance, behaviour characteristics, and changes in body temperature and body weight of the rats in each subgroup were comparable to the normal control subgroup. Except for a few cases, there were no lesions in the viscera’s pathological structures, and the blood parameters and biochemical indicators were not noticeably different from those of the control subgroup. Conclusion This study suggests that rBoIFN-α seems to be safe for rats, and its use may foster the development of the cattle industry in China by protecting livestock health.

show abstract

Treatment response and adverse effects of direct acting antivirals among HCV patients carrying comorbid conditions

Nishwa,

Riaz,

Tiwana

et al. 2024

Future Virology

View full text Add to dashboard Cite

Aim: Our study aimed to assess the response to direct-acting antiviral drugs (DAAs) among hepatitis C virus (HCV)-infected patients who also had other comorbid conditions. Materials & methods: The data was examined based on a variety of categories, encompassing age, gender, liver function enzymes, tumor markers and comorbid conditions. Results: In conclusion, DAAs demonstrated relatively effective results in HCV/hepatitis B virus coinfected patients, with a 78.2% sustained virological response rate, and 55.5% among HCV monoinfected patients in our study sample. However, some challenges remain, as we observed certain adverse effects associated with DAAs. Conclusion: In the past, interferon-based treatment regimens were the primary options against HCV; however, their limited success led to the development of DAAs drugs that reportedly cause adverse outcomes occasionally.

show abstract

Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin)

Cited by 4 publications

References 10 publications

Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity

Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity

Acute and sub-chronic toxicity study of recombinant bovine interferon alpha in rodents

Treatment response and adverse effects of direct acting antivirals among HCV patients carrying comorbid conditions

Contact Info

Product

Resources

About